Delving into the Latest Updates on RJK-RT2831 with Synapse

Overview

Basic Info

Drug Type

Nanobody

Synonyms

+ [1]

Target-

Mechanism-

Therapeutic Areas

NeoplasmsHemic and Lymphatic Diseases

Active Indication

Hematologic Neoplasms

Inactive Indication-

Originator Organization

RegeneCore Biotech Co., Ltd

Active Organization

RegeneCore Biotech Co., Ltd

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

1.主要目的：评估 RJK-RT2831 在恶性血液肿瘤受试者中的安全性、耐受性和最大耐受剂量。确定 RJK-RT2831 治疗恶性血液肿瘤受试者的扩展期推荐剂量。 2.次要目的：评估 RJK-RT2831 在恶性血液肿瘤受试者中单、多次给药的药代动力学特征。评估 RJK-RT2831 在恶性血液肿瘤受试者中的初步抗肿瘤活性。评估 RJK-RT2831 在恶性血液肿瘤受试者中的免疫原性。

[Translation]

1. Primary objectives: To evaluate the safety, tolerability and maximum tolerated dose of RJK-RT2831 in subjects with hematological malignancies. To determine the recommended dose of RJK-RT2831 for the extension phase of the treatment of subjects with hematological malignancies. 2. Secondary objectives: To evaluate the pharmacokinetic characteristics of single and multiple administrations of RJK-RT2831 in subjects with hematological malignancies. To evaluate the preliminary anti-tumor activity of RJK-RT2831 in subjects with hematological malignancies. To evaluate the immunogenicity of RJK-RT2831 in subjects with hematological malignancies.

Start Date-

Sponsor / Collaborator

RegeneCore Biotech Co., Ltd

100 Clinical Results associated with RJK-RT2831

Login to view more data

100 Translational Medicine associated with RJK-RT2831

Login to view more data

100 Patents (Medical) associated with RJK-RT2831

Login to view more data

100 Deals associated with RJK-RT2831

Login to view more data